Interpace Biosciences Announces Record Date for Proposed Fully Back-Stopped $30 Million Rights Offering
January 03, 2022 17:07 ET
|
Interpace Biosciences, Inc.
Proceeds to be used to fund the organic growth and prospective product line acquisitions PARSIPPANY, NJ, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”)...
Interpace Biosciences Announces Executive Transition: Jack Stover to Retire as President and Chief Executive Officer Thomas Burnell Appointed as Successor
November 25, 2020 08:12 ET
|
Interpace Biosciences, Inc.
Parsippany, NJ, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) today announced that Jack Stover, President & Chief Executive Officer, will retire effective December...
Interpace to Host Conference Call and Webcast to Discuss Third Quarter 2019 Financial Results on Wednesday, November 13, 2019
November 12, 2019 06:55 ET
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Interpace (IDXG) announced today that it will report its third quarter 2019 financial results on Wednesday, November 13, 2019 at 4:30 p.m. ET....